Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nasus Pharma Ltd
Report date July 22, 2026 · Filed July 29, 2026
Section 16 reporting ended · disclosed 2026-07-29. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 11:12 UTC | Nasus Pharma Ltd NSRX · Entity 7254 | PurchaseOrdinary Shares | 6,550 | $3.10 | $20,305.00 |
DisclosureSEC source: 0001493152-26-029484 · ownership.xml · nonDerivative · entry 1 Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,541 F1 · balance_after: Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 01:44 UTC | Nasus Pharma Ltd NSRX · Entity 7254 | PurchaseOrdinary Shares | 2,900 | $3.76 | $10,904.00 |
DisclosureSEC source: 0001493152-26-018607 · ownership.xml · nonDerivative · entry 1 Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,991 F1 · balance_after: Consists of: (i) 24,146 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 11:31 UTC | Nasus Pharma Ltd NSRX · Entity 7254 | PurchaseOrdinary Shares | 15,000 | $2.04 | $30,600.00 |
DisclosureSEC source: 0001493152-26-014503 · ownership.xml · nonDerivative · entry 1 Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,246 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.